Several clinical trials are ongoing to assess the safety and efficacy of CAR‐T cells using different GBM‐associated antigens such as EGFRvIII, NKG2D, B7‐H3, CD147, IL13Ralpha2, and HER2. This evidence concerns the gene KLRK1 and glioblastoma.